Nurix Therapeutics, Inc.
For the period ended Nov 30, 2025. Filed Jan 28, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Jan 28, 2026
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(in thousands)
| Year Ended November 30, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(264,457) | $(193,569) | $(143,948) |
| Other comprehensive loss, net of tax: | |||
| Unrealized gain (loss) on available-for-sale marketable securities | (45) | 805 | 3,664 |
| Total comprehensive loss | $(264,502) | $(192,764) | $(140,284) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.